Trending NewsTrending NewsTop-Rated Dividend StocksTop-Rated DividendMost-Upgraded StocksMost-UpgradedNYSE:ABBV AbbVie (ABBV) Stock Price, News & Analysis $293.90 +7.91 (+2.76%) As of 03:46 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About AbbVie Stock (NYSE:ABBV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AbbVie alerts:Sign Up Key Stats Today's Range$283.32▼$294.1950-Day Range$248.75▼$294.8052-Week Range$190.75▼$298.74Volume4.69 million shsAverage Volume6.33 million shsMarket Capitalization$519.27 billionP/E Ratio50.53Dividend Yield2.35%Price Target$297.46Consensus RatingModerate Buy Company Overview AbbVie Inc. (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world. The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta. Through its Allergan aesthetics business, AbbVie also offers Botox Cosmetic, dermal fillers and other aesthetic treatments. The company’s earlier flagship product, Humira, was used to treat several inflammatory conditions and was one of the world’s leading pharmaceutical products before biosimilar competition began. AbbVie became an independent company in 2013 after being separated from Abbott Laboratories. Its acquisition of Allergan, completed in 2020, expanded its presence in medical aesthetics, eye care and other specialty markets. AbbVie is headquartered in North Chicago, Illinois, and is led by Chief Executive Officer Robert A. Michael.AI Generated. May Contain Errors. Read More AbbVie Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreABBV MarketRank™: 4.413411545125 of 5 starsAbbVie scored higher than 88% of companies evaluated by MarketBeat, and ranked 7th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.6 / 5Analyst RatingModerate Buy Consensus RatingAbbVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 22 buy ratings, 6 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for AbbVie is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAbbVie has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AbbVie's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth15.14% Earnings GrowthEarnings for AbbVie are expected to grow by 15.14% in the coming year, from $14.00 to $16.12 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AbbVie is 50.21, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.15.Price to Earnings Ratio vs. SectorThe P/E ratio of AbbVie is 50.21, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.48.Price to Earnings Growth RatioAbbVie has a PEG Ratio of 1.31. PEG Ratios above 1 indicate that a company could be overvalued. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.88% of the float of AbbVie has been sold short.Short Interest Ratio / Days to CoverAbbVie has a short interest ratio ("days to cover") of 2.72, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AbbVie has recently decreased by 4.29%, indicating that investor sentiment is improving. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldAbbVie pays a meaningful dividend of 2.40%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAbbVie has been increasing its dividend for 53 years.Dividend CoverageThe dividend payout ratio of AbbVie is 119.10%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, AbbVie will have a dividend payout ratio of 42.93% next year. This indicates that AbbVie will be able to sustain or increase its dividend.Read more about AbbVie's dividend. News and Social Media4.3 / 5News Sentiment0.94 News SentimentAbbVie has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 113 news articles for AbbVie this week, compared to 10 articles on an average week.Search Interest93 people have searched for ABBV on MarketBeat in the last 30 days. This is an increase of 26% compared to the previous 30 days.MarketBeat Follows94 people have added AbbVie to their MarketBeat watchlist in the last 30 days. This is an increase of 276% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,177,500.00 in company stock.Percentage Held by Insiders0.06% of the stock of AbbVie is held by insiders.Percentage Held by Institutions70.23% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AbbVie's insider trading history. Receive ABBV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABBV Stock News HeadlinesAbbVie, Nxera ink licensing deal worth up to $1.5B for bowel disease therapy8 minutes ago | seekingalpha.comAbbVie Enters Global License Deal With Nxera Pharma for Experimental IBD DrugNovember 4 at 9:51 AM | finance.yahoo.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 4 at 1:00 AM | Behind the Markets (Ad)Exxon Mobil Just Raised Its Dividend for the 44th Year. Here Are 3 More Wall Street FavoritesNovember 4 at 8:37 AM | 247wallst.comNxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel DiseaseNovember 4 at 4:46 AM | finance.yahoo.comNxera Raises 2026 Forecast After AbbVie Licensing DealNovember 4 at 2:10 AM | tipranks.comAbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another TestAbbVie posted Q3 revenue of $17.4 billion and raised EPS guidance as Skyrizi and Rinvoq offset Humira's decline, prompting analyst price target hikes and a stock move to fresh highs.November 2 at 1:15 PM | marketbeat.com3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach (ABBV)Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.October 23, 2026 | marketbeat.comSee More Headlines ABBV Stock Analysis - Frequently Asked Questions How have ABBV shares performed this year? AbbVie's stock was trading at $228.55 on January 1st, 2026. Since then, ABBV stock has increased by 27.7% and is now trading at $291.94. How were AbbVie's earnings last quarter? AbbVie Inc. (NYSE:ABBV) posted its quarterly earnings results on Friday, October, 30th. The company reported $3.82 earnings per share for the quarter, beating the consensus estimate of $3.73 by $0.09. The company's quarterly revenue was up 10.3% on a year-over-year basis. Read the conference call transcript. Does AbbVie have any subsidiaries? The following companies are subsidiaries of AbbVie: Mavupharma, Allergan, Stem CentRx, Pharmacyclics Inc, ImmuVen, AbbVie AB, AbbVie AG, and others. Who are AbbVie's major shareholders? AbbVie's top institutional shareholders include Sumitomo Mitsui Trust Group Inc. (0.22%), Robeco Institutional Asset Management B.V. (0.21%), Assenagon Asset Management S.A. (0.10%) and ProShare Advisors LLC (0.05%). Insiders that own company stock include Richard A Gonzalez, Azita Saleki-Gerhardt, Robert A Michael, Nicholas Donoghoe, Jeffrey Ryan Stewart, Timothy J Richmond, Perry C Siatis, Scott T Reents, Kevin K Buckbee and David Ryan Purdue. View institutional ownership trends. How do I buy shares of AbbVie? Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AbbVie own? Based on aggregate information from My MarketBeat watchlists, some other companies that AbbVie investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Chevron (CVX) and ExxonMobil (XOM). Company Calendar Record date for 8/14 Dividend7/15/2026Ex-Dividend for 8/14 Dividend7/15/2026Dividend Payable8/14/2026Record date for 11/16 Dividend10/15/2026Ex-Dividend for 11/16 Dividend10/15/2026Last Earnings10/30/2026Today11/04/2026Dividend Payable11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ABBV's financial health is in the Green zone, according to TradeSmith. ABBV has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:ABBV CIK1551152 Webwww.abbvie.com Phone(847) 932-7900Fax302-655-5049Employees57,000Year Founded2013Price Target and Rating Average Price Target for AbbVie$297.46 High Price Target$346.00 Low Price Target$235.00 Potential Upside/Downside+1.9%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage29 Analysts Profitability EPS (Trailing Twelve Months)$5.81 Trailing P/E Ratio50.24 Forward P/E Ratio18.11 P/E Growth1.31Net Income$4.23 billion Net Margins15.67% Pretax Margin19.41% Return on Equity-435.41% Return on Assets16.89% Debt Debt-to-Equity RatioN/A Current Ratio0.81 Quick Ratio0.69 Sales & Book Value Annual Sales$61.16 billion Price / Sales8.43 Cash Flow$15.31 per share Price / Cash Flow19.07 Book Value($1.83) per share Price / Book-159.49Miscellaneous Outstanding Shares1,766,790,000Free Float1,765,733,000Market Cap$515.68 billion OptionableOptionable Beta0.20 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NYSE:ABBV) was last updated on 11/4/2026 by MarketBeat.com Staff. From Our PartnersThe AI Infrastructure Rush Is ON — Watch VDTAVertical Data Inc (OTCQB: VDTA) is building the layers beneath the AI boom - GPU hardware and financing, manag...Trading Wire | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredU.S. Army Advances 75-Year Rare Earth Deal With Nasdaq FirmThe Pentagon is moving to cut US dependence on Chinese rare earth metals, and a Nasdaq-listed company just sig...The Tomorrow Investor | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbbVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbbVie With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
